The University of Southampton
University of Southampton Institutional Repository

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial

Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial
Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial

Background: Adverse effects on reproductive function are a key concern in young women treated with chemotherapy for advanced Hodgkin's lymphoma. We aimed to identify risk factors for the extent of ovarian damage in women with Hodgkin's lymphoma treated with different chemotherapy regimens to inform accurate advice on options for fertility preservation. Methods: We recruited female participants from the randomised phase 3 RATHL trial, aged 18–45 years, based on availability of participants at recruiting sites in the UK. The RATHL trial key inclusion criteria were histologically confirmed classic Hodgkin's lymphoma, stage IIB–IV or IIA with adverse features (bulky disease or more than two sites of involvement), no previous treatments, and a performance status of 0–3. As part of RATHL, participants were treated with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or AVD followed by an interim PET-CT scan. Participants who had negative interim scans (PET score of 1 to 3 according to the Lugano classification) were randomly assigned (1:1) by use of minimisation, stratified by interim PET score and study centre, to continue ABVD or AVD for four more cycles. Participants with positive scans (PET score of 4 or 5) were escalated to treatment with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone (BEACOPP-14 or escalated BEACOPP) for four cycles. For the protocol-driven prospective cohort substudy, ovarian function was assessed before treatment, during chemotherapy, and then annually for 3 years by use of serum antimüllerian hormone and follicle-stimulating hormone measurements. The RATHL study is registered with ClinicalTrials.gov, number NCT00678327. Findings: Between Dec 13, 2010, and Dec 19, 2012, 67 eligible participants were recruited for this prospective cohort study; 57 had received ABVD or AVD (ABVD-AVD group) and ten BEACOPP-14 or escalated BEACOPP (BEACOPP group). Follow-up was fixed at 3 years. Antimüllerian hormone concentrations decreased during both chemotherapy regimens. At 1 year after chemotherapy, antimüllerian hormone concentrations recovered to a median of 10·5 pmol/L (IQR 4·3–17·3) in the ABVD-AVD group, but little recovery was seen after BEACOPP (median 0·11 pmol/L [0·07–0·20]). Age also affected the extent of ovarian function recovery, with antimüllerian hormone recovery in participants aged 35 years or older in the ABVD-AVD group to 37% (SD 10) of their before treatment concentrations, compared with full recovery to 127% (SD 12) in those younger than 35 years (p<0·0001). Follicle-stimulating hormone recovery to less than 25 IU/L occurred for 95% of women younger than 35 years in the ABVD-AVD group by 2 years and was also dependent on age (hazard ratio 0·49, 95% CI 0·37–0·65; p<0·0001). Interpretation: Reduced recovery of ovarian function observed in women older than 35 years treated with ABVD or AVD compared with younger women indicates that treatment could reduce their reproductive lifespan and supports discussion of fertility preservation before treatment. Women treated with BEACOPP should be informed of its potential high gonadotoxicity. These findings warrant further investigation in large, prospective studies with fertility and reproductive lifespan as outcomes. Funding: Medical Research Foundation and Cancer Research UK.

1470-2045
1328-1337
Anderson, Richard A.
ad1cbca8-d660-4fc8-a382-4c2b91c3d3ed
Remedios, Rachel
55dbf785-dbe0-4ced-8d83-8a38323b317c
Kirkwood, Amy A.
2aab471d-be8f-4662-917b-590b1d705110
Patrick, Pip
6dd704ce-3b0a-4238-882c-9ada4ab8f347
Stevens, Linsey
f7bcd779-d3bf-4f5f-b9f2-02cfe00dc4d5
Clifton-Hadley, Laura
103618aa-8c40-4c6e-ac12-0d0164c90277
Roberts, Tom
13aa9e20-ebf2-4b7c-821e-1dc593f79856
Hatton, Chris
41579848-ec0e-4536-bbff-c932bf88aca5
Kalakonda, Nagesh
c3b15004-be3f-4fd8-afee-9f1c3a664a0b
Milligan, Don W.
bb3face3-d68e-43b2-afdf-51cac70f346f
McKay, Pam
2d7af351-e33a-4b04-abe4-74542298f292
Rowntree, Clare
9809bb44-09c2-405a-9534-e09d1ec1db65
Scott, Fiona M.
e1519050-6f94-4cbb-a059-5da2fec382cb
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Anderson, Richard A.
ad1cbca8-d660-4fc8-a382-4c2b91c3d3ed
Remedios, Rachel
55dbf785-dbe0-4ced-8d83-8a38323b317c
Kirkwood, Amy A.
2aab471d-be8f-4662-917b-590b1d705110
Patrick, Pip
6dd704ce-3b0a-4238-882c-9ada4ab8f347
Stevens, Linsey
f7bcd779-d3bf-4f5f-b9f2-02cfe00dc4d5
Clifton-Hadley, Laura
103618aa-8c40-4c6e-ac12-0d0164c90277
Roberts, Tom
13aa9e20-ebf2-4b7c-821e-1dc593f79856
Hatton, Chris
41579848-ec0e-4536-bbff-c932bf88aca5
Kalakonda, Nagesh
c3b15004-be3f-4fd8-afee-9f1c3a664a0b
Milligan, Don W.
bb3face3-d68e-43b2-afdf-51cac70f346f
McKay, Pam
2d7af351-e33a-4b04-abe4-74542298f292
Rowntree, Clare
9809bb44-09c2-405a-9534-e09d1ec1db65
Scott, Fiona M.
e1519050-6f94-4cbb-a059-5da2fec382cb
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f

Anderson, Richard A., Remedios, Rachel, Kirkwood, Amy A., Patrick, Pip, Stevens, Linsey, Clifton-Hadley, Laura, Roberts, Tom, Hatton, Chris, Kalakonda, Nagesh, Milligan, Don W., McKay, Pam, Rowntree, Clare, Scott, Fiona M. and Johnson, Peter W.M. (2018) Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial. The Lancet Oncology, 19 (10), 1328-1337. (doi:10.1016/S1470-2045(18)30500-X).

Record type: Article

Abstract

Background: Adverse effects on reproductive function are a key concern in young women treated with chemotherapy for advanced Hodgkin's lymphoma. We aimed to identify risk factors for the extent of ovarian damage in women with Hodgkin's lymphoma treated with different chemotherapy regimens to inform accurate advice on options for fertility preservation. Methods: We recruited female participants from the randomised phase 3 RATHL trial, aged 18–45 years, based on availability of participants at recruiting sites in the UK. The RATHL trial key inclusion criteria were histologically confirmed classic Hodgkin's lymphoma, stage IIB–IV or IIA with adverse features (bulky disease or more than two sites of involvement), no previous treatments, and a performance status of 0–3. As part of RATHL, participants were treated with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or AVD followed by an interim PET-CT scan. Participants who had negative interim scans (PET score of 1 to 3 according to the Lugano classification) were randomly assigned (1:1) by use of minimisation, stratified by interim PET score and study centre, to continue ABVD or AVD for four more cycles. Participants with positive scans (PET score of 4 or 5) were escalated to treatment with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone (BEACOPP-14 or escalated BEACOPP) for four cycles. For the protocol-driven prospective cohort substudy, ovarian function was assessed before treatment, during chemotherapy, and then annually for 3 years by use of serum antimüllerian hormone and follicle-stimulating hormone measurements. The RATHL study is registered with ClinicalTrials.gov, number NCT00678327. Findings: Between Dec 13, 2010, and Dec 19, 2012, 67 eligible participants were recruited for this prospective cohort study; 57 had received ABVD or AVD (ABVD-AVD group) and ten BEACOPP-14 or escalated BEACOPP (BEACOPP group). Follow-up was fixed at 3 years. Antimüllerian hormone concentrations decreased during both chemotherapy regimens. At 1 year after chemotherapy, antimüllerian hormone concentrations recovered to a median of 10·5 pmol/L (IQR 4·3–17·3) in the ABVD-AVD group, but little recovery was seen after BEACOPP (median 0·11 pmol/L [0·07–0·20]). Age also affected the extent of ovarian function recovery, with antimüllerian hormone recovery in participants aged 35 years or older in the ABVD-AVD group to 37% (SD 10) of their before treatment concentrations, compared with full recovery to 127% (SD 12) in those younger than 35 years (p<0·0001). Follicle-stimulating hormone recovery to less than 25 IU/L occurred for 95% of women younger than 35 years in the ABVD-AVD group by 2 years and was also dependent on age (hazard ratio 0·49, 95% CI 0·37–0·65; p<0·0001). Interpretation: Reduced recovery of ovarian function observed in women older than 35 years treated with ABVD or AVD compared with younger women indicates that treatment could reduce their reproductive lifespan and supports discussion of fertility preservation before treatment. Women treated with BEACOPP should be informed of its potential high gonadotoxicity. These findings warrant further investigation in large, prospective studies with fertility and reproductive lifespan as outcomes. Funding: Medical Research Foundation and Cancer Research UK.

Text
1-s2.0-S147020451830500X-main - Version of Record
Download (432kB)

More information

e-pub ahead of print date: 13 September 2018
Published date: 1 October 2018

Identifiers

Local EPrints ID: 425707
URI: https://eprints.soton.ac.uk/id/eprint/425707
ISSN: 1470-2045
PURE UUID: 258a7733-61f2-442f-b609-782f8eb7ea17
ORCID for Peter W.M. Johnson: ORCID iD orcid.org/0000-0003-2306-4974

Catalogue record

Date deposited: 01 Nov 2018 17:30
Last modified: 14 Mar 2019 01:49

Export record

Altmetrics

Contributors

Author: Richard A. Anderson
Author: Rachel Remedios
Author: Amy A. Kirkwood
Author: Pip Patrick
Author: Linsey Stevens
Author: Laura Clifton-Hadley
Author: Tom Roberts
Author: Chris Hatton
Author: Nagesh Kalakonda
Author: Don W. Milligan
Author: Pam McKay
Author: Clare Rowntree
Author: Fiona M. Scott

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×